Prescription Required: Registered Medical Practitioner's prescription is required to purchase this product.

Human

Lenor®

Tablet

2.5 mg

GENERIC NAMELetrozole

MANUFACTURED BYEskayef Pharmaceuticals Ltd.

Compare Brands

Available Pack Sizes:1 Size

Purchase Option:Full Pack

Maximum Retail Price (MRP):

Quantity

৳ 360.00/ 10 x 1

(Unit: ৳ 40.00 / 1 Tablet)

16263

Composition

Lenor® Tablet: Each film-coated tablet contains Letrozole USP 2.5 mg.

Description

Lenor® is a preparation Letrozole. Letrozole is a non-steroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitively binding to the haem of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. The suppression of estrogen biosynthesis in peripheral tissues and the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme.

Indications

Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years prior standard adjuvant tamoxifen therapy.

First-line treatment in postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer.

Treatment of advanced breast cancer in women with natural or artificially induced postmenopausal status, who have previously been treated with antiestrogens.

Dosage & Administration

Adult & Elderly patients: The recommended dose of Lenor® is 2.5 mg once daily. In the adjuvant and extended adjuvant setting, treatment with Lenor® should continue for 5 years or until tumour relapse occurs, whichever comes first. In patients with metastatic disease, treatment with Lenor® should continue until tumour progression is evident. No dose adjustment is required for elderly patients.

Renal Impairment: No dosage adjustment is required for patients with renal impairment if creatinine clearance is ≥10 ml/ min.

Children: Not applicable.

Hepatic Impairment: No dosage adjustment is required for patients with mild to moderate hepatic impairment. The dose of Lenor® in patients with cirrhosis and severe hepatic impairment should be reduced by 50%. The recommended dose for such patient is 2.5 mg administered every other day. The effect of hepatic impairment on Lenor® exposure in noncirrhotic women patients with elevated bilirubin level has not been determined.

Contraindications

In women having a premenopausal endocrine status, during pregnancy & lactation.

Known hypersensitivity to the active substance.

Side Effects

Letrozole tablet is generally well tolerated.

The observed adverse reactions are mild to moderate in nature including hot ash, night sweats, weight increase, nausea, vaginal bleeding & irritation, endometrial proliferation disorders.

Pregnancy & Lactation

Contraindicated during pregnancy and lactation.

Storage Conditions

Keep in a dry & cool place (below 30°C temp.), away from light. Keep out of reach of children.

Lenor® • 10 x 1

৳ 360.00